No Data
Express News | Foghorn Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People With HIV
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People With HIV and Multidrug Resistance
Theratechnologies Analyst Ratings
Earnings Call: Theratechnologies Reports Q3 Profit, Raises EBITDA Guidance
JonesTrading Downgrades Theratechnologies(THTX.US) to Hold Rating
No Data